Elevance Health, Inc. operates a health benefits and healthcare services platform built around affiliated health plans and the Carelon services business. Recurring company news covers Health Benefits results, premium yields, medical-cost trends, Medicaid, Medicare Advantage and employer group membership, and Carelon activity in pharmacy services, behavioral health, value-based care, care delivery, clinical, home health and complex care solutions.
Company updates also address small and midsize employer benefit offerings such as Balanced Funding and MEWAs, primary-care recognition and value-based provider programs, partnerships tied to family and community health, annual and quarterly financial guidance, and leadership changes across Health Benefits and Carelon.
Elevance Health (NYSE: ELV) has scheduled its third quarter 2025 financial results announcement for October 21, 2025. The company will release results at 6:00 a.m. EDT, followed by a management conference call at 8:30 a.m. EDT to discuss the results and outlook.
Investors can access the conference call using specific dial-in numbers and access codes for both domestic and international participants. A replay will be available from 11:30 a.m. EDT on October 21 until November 21, 2025. Additionally, a live webcast will be accessible through the company's website at www.elevancehealth.com under the "Investors" section.
Elevance Health (NYSE:ELV) and the Impact Fitness Foundation have partnered to transform Northwest Middle School's weight room in Indianapolis. The renovation project, which marks the fourth fitness space upgrade in Indianapolis schools, includes new flooring, functional training equipment, and storage systems designed specifically for middle school students.
The initiative aligns with the Elevance Health Women's Fort Myers Tipoff basketball tournament and involved over 30 Elevance Health volunteers. The project aims to provide students with their first experience in a proper fitness facility, replacing previously outdated high school-level equipment that was unsuitable for middle school use.
Elevance Health (NYSE:ELV) has partnered with the National Association of Community Health Centers (NACHC) to integrate Food as Medicine (FAM) programming into primary care Community Health Centers (CHCs). The initiative expands Elevance's Nourished Well program by training CHC providers to connect Medicaid members at risk for diet-related chronic conditions with personalized nutrition support.
The partnership implements a three-pillar FAM Ecosystem Framework: food access & security through telehealth, clinical integration within primary care workflows, and culturally relevant lifestyle interventions. Additionally, the Elevance Health Foundation will provide a grant to NACHC to assess existing FAM programs, evaluate policies, and develop a scalable CHC model.
The program aims to enhance patient engagement, support chronic disease management, and strengthen preventive health efforts across CHCs serving 34 million patients nationwide. The long-term vision includes developing a Nutrition Center of Excellence as a national model for food-based clinical care.
Elevance Health (NYSE: ELV) has appointed Steve Collis to its Board of Directors, effective August 1, 2025. Collis, who currently serves as Executive Chairman of Cencora (formerly AmerisourceBergen), will join the board's Audit and Finance Committees.
Collis brings significant healthcare leadership experience, having served as President and CEO of Cencora from 2011 to 2024, where he led the company through strategic transformation and global expansion. The appointment aligns with Elevance Health's structured approach to board refreshment and strengthens its governance capabilities in support of the company's strategic objectives.
Elevance Health (NYSE:ELV) and UC Irvine have released results from a groundbreaking clinical trial demonstrating the effectiveness of a digital asthma self-management (DASM) program. The study, involving 901 adult participants across 41 U.S. states, showed significant improvements in asthma symptom control over 12 months.
Participants with uncontrolled asthma using the DASM program, which integrated iPhone and Apple Watch technology, saw their Asthma Control Test scores improve by 4.6 points, compared to 1.8 points in the control group. The program demonstrated benefits across insurance types and ethnicities, though effects were lower among African American participants. Secondary benefits included improved medication adherence and enhanced work productivity.
Elevance Health (NYSE:ELV) reported Q2 2025 results with operating revenue of $49.4 billion, up 14.3% year-over-year. The company revised its FY 2025 guidance, now expecting adjusted EPS of approximately $30.00.
Key metrics show mixed performance: benefit expense ratio increased 260 basis points to 88.9%, while operating expense ratio improved 160 basis points to 10.1%. Medical membership declined by 212,000 to 45.6 million members. The company returned $2.0 billion to shareholders year-to-date through dividends and share repurchases.
The Health Benefits segment generated $41.6 billion in revenue, while Carelon's revenue grew 36% to $18.1 billion. The company declared a Q3 2025 dividend of $1.71 per share.
Elevance Health (NYSE: ELV) has scheduled its second quarter 2025 financial results announcement for July 17, 2025. The company will release results at 6:00 a.m. EDT, followed by a management conference call at 8:30 a.m. EDT to discuss the results and outlook.
Investors can access the conference call using specific dial-in numbers and access codes for both domestic and international participants. A replay will be available from 11:30 a.m. EDT on July 17 until August 15, 2025. Additionally, a live webcast will be accessible through the company's website at www.elevancehealth.com under the "Investors" section.
Elevance Health (NYSE: ELV) reported strong Q1 2025 financial results with operating revenue reaching $48.8 billion, up 15.4% year-over-year. The company achieved an adjusted operating gain of $3.3 billion, representing a 4.1% increase from Q1 2024.
Key financial metrics include diluted EPS of $9.61 and adjusted diluted EPS of $11.97. The company reaffirmed its FY 2025 adjusted diluted EPS guidance of $34.15 to $34.85. During Q1, Elevance returned $1.3 billion to shareholders through share repurchases ($880 million) and dividends ($386 million).
The Health Benefits segment generated $41.4 billion in operating revenue, while Carelon's revenue grew 38% to $16.7 billion. Medical membership increased by 99,000 from year-end 2024, reaching approximately 45.8 million members. The company declared a Q2 2025 dividend of $1.71 per share, payable on June 25, 2025.
Elevance Health (NYSE: ELV) has announced it will release its first quarter 2025 financial results on April 22, 2025, at 6:00 a.m. EDT. The company will host a conference call at 8:30 a.m. EDT the same day to discuss the results and outlook.
Participants can access the call using the following numbers:
- Domestic: 888-947-9963 (Access Code: 3972058)
- International: 312-470-0178 (Access Code: 3972058)
A replay will be available from 11:30 a.m. EDT on April 22 until May 22, 2025, through:
- Domestic: 800-396-1242
- International: 203-369-3272
Elevance Health (NYSE: ELV) reported Q4 2024 operating revenue of $45.0 billion, up 6% year-over-year, and full-year 2024 revenue of $175.2 billion, a 3% increase. The company's Q4 2024 adjusted diluted EPS was $3.84, while full-year adjusted EPS reached $33.04.
The benefit expense ratio increased to 92.4% in Q4, up 320 basis points from the previous year, primarily due to higher Medicaid medical cost trends. The company's operating cash flow was $5.8 billion in 2024. During Q4, Elevance repurchased 4.5 million shares for $1.8 billion and increased its quarterly dividend by 5% to $1.71 per share.
Medical membership decreased by 1.1 million to 45.7 million members, mainly due to Medicaid business attrition. Looking ahead, Elevance projects FY 2025 adjusted EPS to be between $34.15 and $34.85.